Nina Kola
About Nina Kola
Nina Kola is the Executive Director, Medical Safety Assessment Therapeutic Area Lead for Solid Tumor Oncology at Bristol Myers Squibb in Princeton, New Jersey, with over 15 years of experience in pharmacovigilance and medical safety assessment.
Current Role at Bristol Myers Squibb
Nina Kola serves as the Executive Director, Medical Safety Assessment Therapeutic Area Lead for Solid Tumor Oncology at Bristol Myers Squibb in Princeton, New Jersey. In this role, she is responsible for overseeing the medical safety assessment and ensuring the safety of oncology therapeutics. Her work focusses on solid tumors, where she applies her expertise in medical safety to drive therapeutic advancements and maintain patient safety.
Previous Positions at Bristol Myers Squibb
Before her current role, Nina Kola held several key positions at Bristol Myers Squibb. In 2020, she worked as Group Medical Director, Medical Safety Assessment Therapeutic Area Lead for Solid Tumor Oncology for 7 months in Princeton, New Jersey. Prior to that, she spent 5 years from 2015 to 2020 as Medical Director, Medical Safety Assessment Physician, Immuno-Oncology at the same location. These roles involved leading safety assessments and contributing to the development and monitoring of oncology therapies.
Experience at Amgen and Takeda
Nina Kola has also played significant roles outside of Bristol Myers Squibb. She served as Global Safety Director at Amgen from 2013 to 2014 in Uxbridge. At Takeda Global Research & Development (Europe) Ltd, she was Medical Director, Pharmacovigilance from 2011 to 2013, and at Takeda Pharmaceuticals, she was Associate Medical Director, Pharmacovigilance from 2009 to 2011. Her responsibilities at these companies included directing global safety initiatives and managing pharmacovigilance efforts to ensure drug safety.
Career at Wyeth Pharmaceuticals
Earlier in her career, Nina Kola worked for Wyeth Pharmaceuticals from 2005 to 2009. During her tenure, she held roles as Medical Adviser and Senior Patient Safety Physician. Her focus was on patient safety and pharmacovigilance, laying the foundation for her specialized career in medical safety assessment.
Expertise in Pharmacovigilance and Oncology
With over 15 years of experience in pharmacovigilance and medical safety assessment, Nina Kola has extensive expertise in these fields. She has held leadership roles in both immuno-oncology and solid tumor oncology therapeutic areas. Her career trajectory shows a transition from general pharmacovigilance roles to specialized positions focused on the safety of oncology therapeutics. She has led safety assessments for major pharmaceutical companies, reflecting a comprehensive understanding of drug safety.